文献速递骨质疏松与钙磷/甲状旁腺性腺与生殖内分泌

功能性下丘脑性闭经骨密度药物干预:系统综述与网状Meta分析

Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

透皮激素替代治疗改善腰椎(SMD 0.34)和股骨颈(SMD 0.57)骨密度;特立帕肽改善腰椎骨密度优于透皮HRT和COCP;口服HRT和COCP无显著获益。

要点

  • 透皮HRT可显著改善腰椎和股骨颈骨密度。
  • 特立帕肽对腰椎骨密度改善优于透皮HRT和COCP。
  • 口服HRT和COCP对任何部位骨密度均无显著获益。

核心结论

  • 透皮HRT和特立帕肽可改善FHA女性腰椎骨密度,透皮HRT还改善股骨颈骨密度。

研究设计与样本

  • 检索Medline、Embase、Emcare、Cochrane CENTRAL、ISRCTN和ClinicalTrials.gov至2025年9月20日。
  • 采用随机效应网状Meta分析,效应量为标准化均数差(SMD)及95%CI,证据确定性用CINeMA评估。

主要发现

  • 透皮HRT vs 对照(安慰剂或无干预)改善腰椎BMD:SMD 0.34(0.03,0.64)。
  • 透皮HRT vs 对照改善股骨颈BMD:SMD 0.57(0.04,1.10)。
  • 特立帕肽 vs 透皮HRT改善腰椎BMD:SMD 1.48(0.38,2.59)。
  • 特立帕肽 vs COCP改善腰椎BMD:SMD 1.75(0.66,2.83)。
  • 口服HRT和COCP对腰椎、股骨颈或全髋BMD均无显著获益。

关键数值与推荐

  • 透皮HRT对腰椎BMD的SMD为0.34(95%CI 0.03–0.64),对股骨颈BMD的SMD为0.57(95%CI 0.04–1.10)。
  • 特立帕肽对腰椎BMD优于透皮HRT的SMD为1.48(95%CI 0.38–2.59),优于COCP的SMD为1.75(95%CI 0.66–2.83)。
  • 口服HRT和COCP在任何BMD部位均无显著获益。

临床怎么用

  • 对于FHA女性,透皮HRT可作为改善腰椎和股骨颈骨密度的药物选择。
  • 特立帕肽可考虑用于改善腰椎骨密度,尤其在与透皮HRT或COCP比较时。
  • 口服HRT和COCP不推荐用于改善FHA女性的骨密度。

局限性

  • 全髋BMD分析样本量较小(n=750),股骨颈BMD分析样本量更小(n=370)。
  • 证据确定性采用CINeMA评估,但原文未报告具体分级结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Women with functional hypothalamic amenorrhea (FHA) are at high risk of poor bone health. When lifestyle measures fail to restore menses, pharmacological interventions are needed for bone health, but comparative efficacy remains unclear. OBJECTIVE: To compare the efficacy of available pharmacological interventions to improve bone mineral density (BMD), in women with FHA, employing network meta-analysis (NMA). DATA SOURCES: Medline, Embase, Emcare, Cochrane CENTRAL, ISRCTN, and ClinicalTrials.gov were searched up to 20 September 2025. STUDY SELECTION: Eligible randomized-controlled trials evaluated pharmacological interventions for lumbar spine (LS), femoral neck (FN), or total hip (TH) BMD in women with FHA. Two independent reviewers screened titles, abstracts, and texts. DATA EXTRACTION: Two reviewers independently extracted data following the Preferred Reporting Items for Systematic Reviews-network meta-analysis guidelines. Outcomes were expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs) using random-effects NMA. Evidence certainty was assessed with CINeMA. DATA SYNTHESIS & RESULTS: Thirteen randomized-controlled trials (n = 897 participant observations across all pharmacotherapy comparisons) were included (LS BMD: n = 897; FN BMD: n = 370; TH BMD: n = 750). Transdermal hormone replacement therapy (HRT) was superior to control (placebo or no intervention) for LS BMD with SMD: 0.34 (0.03, 0.64) and FN BMD with SMD: 0.57 (0.04, 1.10). Oral HRT and the combined oral contraceptive pill (COCP) showed no significant benefit for any BMD site. Teriparatide was superior to transdermal HRT and COCP for LS BMD with SMDs: 1.48 (0.38, 2.59) and 1.75 (0.66, 2.83), but not FN or TH BMD. CONCLUSIONS: Transdermal HRT and teriparatide improve LS BMD in women with FHA, with transdermal HRT also improving FN BMD. STUDY REGISTRATION: PROSPERO (CRD42024576872).

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Efthymiadis A, Tsikopoulos K, Mills EG, et al. Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials. J Clin Endocrinol Metab. 2026. PMID: 41505334. doi:10.1210/clinem/dgag005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。